YOLFTbeta
00

PharmGen Science Inc

004720 · KO · Healthcare / Drug Manufacturers - General

3,025.00KRW+55.00 (+1.85%)

Price History

Full chart

Market Stats

Previous Close2,970.00
Open2,950.00
Day Range2,950.00 – 3,060.00
52-Week Range2,590.00 – 4,485.00
Volume23.88K
Market Cap64.45B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.24
50-Day Avg3,138.50
200-Day Avg3,602.15

About

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1966 and is headquartered in Hwaseong-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMr. Hee-Deok Park
  • Employees226
  • Headquarters50, Jeyakgongdan 2-gil, Hwaseong-si, South Korea, 18622, Korea
  • Websitehttps://www.wooridulpharm.com

Leadership

  • Mr. Hee-Deok ParkCEO & Director · b. 1967
  • Ms. Hye-Youn KimChief Executive Officer

Financials

Income Statement

Currency: KRW2004-09-302004-12-312005-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue24.16B12.31B50.63B27.91B30.29B38.97B44.20B60.41B71.55B79.89B89.10B95.14B96.61B109.87B150.93B166.78B171.29B173.07B
Growth (%)--49.04%+311.11%-44.87%+8.53%+28.65%+13.43%+36.65%+18.44%+11.67%+11.52%+6.77%+1.55%+13.72%+37.38%+10.50%+2.70%+1.04%
Cost of Revenue16.67B7.60B28.38B11.80B13.23B16.24B19.67B28.17B31.57B38.64B42.90B44.74B43.02B49.06B69.63B68.91B63.25B61.40B
Gross Profit-----21.88B23.81B32.24B39.98B41.25B46.20B50.40B53.60B60.80B81.30B97.87B108.03B111.68B
Gross Margin-----56.15%53.87%53.37%55.88%51.63%51.85%52.98%55.48%55.34%53.87%58.68%63.07%64.53%
Operating Expense-----25.31B27.42B27.71B35.14B35.24B41.22B49.20B54.05B65.74B73.82B88.74B97.39B105.69B
Operating Income--2.84B---3.43B-3.61B4.52B4.84B6.01B4.99B1.20B-449.91M-4.94B7.48B9.13B10.64B5.99B
Operating Margin--5.62%---8.80%-8.17%7.49%6.76%7.52%5.60%1.26%-0.47%-4.49%4.96%5.47%6.21%3.46%
EBITDA---------7.33B5.37B4.20B14.46B46.81B96.84B16.96B9.81B-145.15B
EBITDA Margin---------9.18%6.02%4.42%14.97%42.61%64.16%10.17%5.73%-83.87%
Net Income--2.36B---3.70B-4.58B2.07B3.45B4.32B4.47B301.98M9.22B32.47B70.06B6.09B2.79B-116.64B
Net Income Margin--4.66%---9.49%-10.37%3.42%4.83%5.41%5.01%0.32%9.55%29.55%46.42%3.65%1.63%-67.39%
R&D---401.36M-503.61M548.25M528.65M694.01M985.83M1.24B886.29M1.11B2.27B2.89B5.12B4.40B4.64B
R&D as % of Total Revenue---1.44%-1.29%1.24%0.88%0.97%1.23%1.39%0.93%1.15%2.07%1.91%3.07%2.57%2.68%
Interest Expense0000000000246.20M1.48B289.55M1.72B3.51B4.26B4.16B1.39B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.28%1.55%0.30%1.57%2.32%2.56%2.43%0.80%

Balance Sheet

Currency: KRW2004-09-302004-12-312005-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets49.90B49.49B66.47B42.82B42.61B39.33B42.04B46.45B64.30B68.48B98.19B100.03B135.54B220.32B317.39B335.92B363.45B195.41B
Total Liabilities24.17B24.58B33.40B24.13B16.71B15.49B21.93B17.79B27.89B17.43B41.35B43.79B51.97B93.39B110.28B107.71B114.02B49.11B
Total Equity25.73B24.91B33.07B18.79B25.86B23.87B20.19B28.71B36.44B50.98B56.74B56.10B83.53B126.94B207.12B228.22B249.44B146.30B
Cash1.36B1.15B3.04B2.18B6.03B813.15M2.56B3.57B5.43B5.18B22.41B11.39B25.92B33.66B19.35B36.91B37.92B21.88B
Net Debt-----------6.21B-13.28B19.20B114.75M318.94M-

Cash Flow

Currency: KRW2004-12-312005-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--2.89B--4.20B-2.02B3.62B7.75B1.84B4.22B2.52B2.68B7.78B-1.29B5.44B2.38B5.32B
Investing Cash Flow--3.28B1.33B-443.68M-1.80B-3.88B-15.82B-2.00B-9.28B-10.95B-7.72B-30.39B----
Financing Cash Flow1.09B14.53B-6.50B-564.68M5.56B1.28B9.93B-82.89M22.30B-2.59B19.57B30.34B----
Capital Expenditure206.55M1.36B642.43M717.46M250.85M403.11M771.87M3.43B1.54B892.34M6.16B4.34B30.75B11.96B3.29B2.78B2.67B
Free Cash Flow--------130.04M3.24B-4.26B-2.79B-26.23B-13.24B2.15B-399.26M2.65B
FCF to OCF--------7.08%76.81%-168.80%-104.19%-336.92%1029.60%39.48%-16.75%49.80%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2022Mar 31, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------------------------------------------------
EPS Actual-107.90-226.38106.41387.43-357.9044.47-612.95161.07-1196.47108.57131.73-93.03-50.00-729.42-64.838.89-125.39-286.76-73.10-60.52-126.28-311.55170.00218.00-133.82164.109.5649.28136.0071.47111.00134.0072.0080.27174.0021.07103.0044.9156.88-12.66-62.31-93.81115.57169.57403.621313.00-471.71255.69-80.9092.83-132.96-17.8897.0054.00-215.73202.66-39.92190.00-121.35-5362.83-45.08-614.00
Surprise--------------------------------------------------------------
Timing--------------------------------------------------------------

Key Statistics & Ratios

Market Cap64.45B
Enterprise Value44.53B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales0.38
Price / Book0.46
Revenue (TTM)171.66B
Gross Profit (TTM)108.36B
EBITDA14.29B
Profit Margin0.07%
Operating Margin4.77%
Return on Equity0.05%
Return on Assets1.76%
Shares Outstanding22.61M
Shares Float13.46M
Beta0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Dec 9, 20141:10
  • Dec 1, 20090.58:1
  • Mar 7, 200610:1